Delaying earnings can be bad too but in this case there is far more potential for a positive catalyst even if there is no deal making. They already intimated they are looking to partner RSV so they can formalize that which means no further clinical development in antivirals after the adult HR study. That would mean a restructuring to a preclinical company effectively which given the cash position should be very good for the stock price.
Market Data 
Markets 
AI
